Co-Diagnostics CEO Dwight Egan delivers manufacturing, commercialization update

Co-Diagnostics announced that in his keynote address at the 5th Annual MarketsandMarkets conference in London, Company CEO Dwight Egan shared an update on the new manufacturing facilities in Salt Lake City, Utah and in Ranoli, India, including announcing the grand opening of the new Utah facility next month. Both Co-Dx and CoSara Diagnostics, the Company’s joint venture for manufacturing in India, will be manufacturing the Co-Dx PCR Pro instrument and Co-Dx PCR test cups that run on the Company’s new PCR platform. Mr. Egan shared that the CoSara facility is in the process of being expanded to allow for greater capacity, and that both facilities would also be manufacturing the Company’s patented Co-Primers oligonucleotides, a key reagent component in all Co-Dx and CoSara test products both for clinical laboratories and the new platform, and which had previously been outsourced to 3rd party manufacturers. In-house manufacturing of the reagents as well as equipment and consumables is anticipated to play an important role as the Company prepares for commercialization of its new platform. In addition to the Co-Dx PCR COVID-19 test on the platform, which is currently pending FDA review, Mr. Egan discussed other forthcoming platform products, including tuberculosis which caused an estimated 1.3 million deaths out of an estimated 10.6 million infections in 2022 despite being highly treatable. The estimated TB incidence rate in India alone was 2.82 million, leading to nearly 350,000 deaths for the year. The ribbon cutting ceremony of the Company’s Salt Lake City production facility is scheduled for April 11, 2024, for Company employees and invitees.